Articles

Arcutis Biotherapeutics said Zoryve foam will be widely available via key wholesaler and dermatology pharmacy channels by the end of January 2024.

FDA Approves Zoryve Topical Foam for Seborrheic Dermatitis

Cloud-based service to address verification of saleable returns under the latest DSCSA regulations.
 


ACG Inspection Presents New VRS

The FDA previously granted the application for Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) with priority review and breakthrough designation for patients with locally advanced or metastatic urothelial cancer.

FDA Approves Padcev Plus Keytruda for Urothelial Cancer 

Breakout session summarizes key areas that will affect all aspects of the industry. 

Trade & Channel Strategies 2023: IRA—All the Things Beyond Price Negotiations That Will Impact Your Business

Creating a meaningful digital transformation requires pharmaceutical manufacturing companies to incorporate the right technologies, processes, and systems to reach their fullest potential. 

Unlocking Pharma 4.0 Through Edge Computing

The FDA based the approval Merck’s Welireg (belzutifan) on findings from the randomized, open-label, Phase III LITESPARK-005 trial, which compared Welireg to Afinitor for the treatment of advanced RCC that has progressed after prior treatment with PD-1/L1 and VEGF-TKI therapies.

FDA Approves HIF-2α Inhibitor for Patients With Advanced Renal Cell Carcinoma

Eflornithine (Iwilfin) is indicated to lower the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who showed at least a partial response to previous multi-agent and multimodality treatment that included an anti-GD2 immunotherapy.

FDA Approves Treatment to Lower Relapse in High-Risk Neuroblastoma 

The conference hosts a diversity, equity, and inclusion (DE&I) Summit featuring personal insights and experiences.

Trade & Channel Strategies 2023: DE&I Within the Life Sciences Space

Pfizer said that the addition of Seagen to its current operations could add more than $10 billion in risk-adjusted revenues by 2030.

Pfizer Close to Completing $43 Billion Acquisition of Seagen

MAPS Public Benefit Corporation was previously granted Breakthrough Therapy Designation by the FDA for MDMA and is seeking a priority review for the NDA submission of the psychedelic treatment for post-traumatic stress disorder.

News